Dr. Ki Hyeong Lee
Claim this profileChungbuk National University Hospital
Expert in Non-Small Cell Lung Cancer
Studies Lung Cancer
15 reported clinical trials
23 drugs studied
Area of expertise
1Non-Small Cell Lung Cancer
Global LeaderStage IV
Stage III
EGFR positive
2Lung Cancer
Stage IV
EGFR positive
Stage III
Affiliated Hospitals
Clinical Trials Ki Hyeong Lee is currently running
Fianlimab + Cemiplimab
for Non-Small Cell Lung Cancer
This trial is testing a new drug combination for patients with advanced lung cancer. It aims to see if using two drugs together is more effective than one alone. The study also looks at side effects, how the drugs are processed in the body, and their impact on quality of life.
Recruiting0 awards Phase 2 & 3
JIN-A02
for Non-Small Cell Lung Cancer
This study is a Phase I/II open-label, multi-center study to evaluate the safety, tolerability, PK, and an anti-tumor activity of JIN-A02, a 4th generation EGFR-TKI agent for oral administration, in EGFR mutant-positive, advanced NSCLC subjects who showed disease progression after receiving standard anticancer therapy, including approved EGFR-TKI therapy and/or no more than a single platinum-based anticancer chemotherapy. In Part A of the study, dose escalation is carried out where MTD is evaluated using Bayesian Optimal Interval (BOIN) design in subjects with advanced NSCLC harboring EGFR-mutation of C797S or T790M. In Part B, dose exploration is carried out to further evaluate the safety of JIN-A02 and to determine the RP2D using 2 preliminary effective dose levels and with the help of a safety review committee (SRC) in advanced NSCLC subjects harboring EGFR mutant C797S or T790M. In Part C dose expansion study, subjects with EGFR mutant who show disease progression after receiving standard anticancer therapy, including approved EGFR-TKI therapy with activity against T790M such as Osimertinib and/or no more than one platinum-based anticancer chemotherapy, are divided into 5 different cohorts based on the EGFR mutation and the anti-tumor activity of JIN-A02 is evaluated. Before enrollment in the study, the EGFR mutant profile is determined using either tumor tissue and/or plasma ctDNA. The profile is determined locally through a test method approved by the sponsor. The sponsor reviews and approves each potential subject for enrollment. Study eligibility evaluation will utilize local test(s).
Recruiting1 award Phase 1 & 212 criteria
More about Ki Hyeong Lee
Clinical Trial Related1 year of experience running clinical trials · Led 15 trials as a Principal Investigator · 11 Active Clinical TrialsTreatments Ki Hyeong Lee has experience with
- Cisplatin
- Pemetrexed
- Cemiplimab
- Fianlimab
- Pembrolizumab
- Docetaxel
Breakdown of trials Ki Hyeong Lee has run
Non-Small Cell Lung Cancer
Lung Cancer
Solid Tumors
Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Ki Hyeong Lee specialize in?
Ki Hyeong Lee focuses on Non-Small Cell Lung Cancer and Lung Cancer. In particular, much of their work with Non-Small Cell Lung Cancer has involved Stage IV patients, or patients who are Stage III.
Is Ki Hyeong Lee currently recruiting for clinical trials?
Yes, Ki Hyeong Lee is currently recruiting for 9 clinical trials in Cheongju-si Chungbuk. If you're interested in participating, you should apply.
Are there any treatments that Ki Hyeong Lee has studied deeply?
Yes, Ki Hyeong Lee has studied treatments such as Cisplatin, Pemetrexed, Cemiplimab.
What is the best way to schedule an appointment with Ki Hyeong Lee?
Apply for one of the trials that Ki Hyeong Lee is conducting.
What is the office address of Ki Hyeong Lee?
The office of Ki Hyeong Lee is located at: Chungbuk National University Hospital, Cheongju-si, Chungbuk 28644 Korea, Republic of. This is the address for their practice at the Chungbuk National University Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.